Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $100.00 price target on the stock.
Frazier Life Sciences Promotes Anna Chen to Partner [Yahoo! Finance]
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $135.00 price target on the stock.